OPSMILL
OpsMill, a pioneer in infrastructure and network automation, today announced that Justin Biegel has joined the company’s Board of Directors as a Board Advisor. Biegel is COO and co-Founder of Kentik, a network observability leader. He will leverage his experience working in network automation, leading GTM efforts, and scaling startups to assist OpsMill strategically as it looks to execute its unique approach to infrastructure and network automation.
“OpsMill is led by a pair of smart founders that have created a groundbreaking solution to the hard problems infrastructure and networking professionals face. Infrahub is an innovative approach to network data management that enables network teams to easily modernize their infrastructure management efforts,” said Justin Biegel, Board Advisor, OpsMill. “They’re coming at just the right time: Network automation is taking off faster than a rocket ship. While we’re still in the early days for network source of truth systems like Infrahub, these systems will prove that they’re a requirement for enterprises to unlock the full potential of network automation. I’m thrilled for the opportunity to work with Damien, Raphael, and the rest of the OpsMill team in a space that I know well from my time founding and building Kentik.”
Biegel brings demonstrated GTM and operational leadership to the role. He has over 10 years of experience working in technology sales and scaling infrastructure and networking companies. During that time, he helped grow Kentik from the ground up as the first head of sales, while serving a diverse roster of customers and broad range of industries across the world.
“Justin brings such value to us as founders as we rapidly grow our company,” said Damien Garros, CEO and co-Founder, OpsMill. “His sales, GTM, and operations background complements our deep technical expertise, forging a partnership that’ll ensure OpsMill maximizes our market reach.”
Biegel co-founded Kentik in 2014 and became COO in 2021. The company has raised $102 million through its series C round of funding. Tech giants Zoom, Box, and Dropbox all use the technology to achieve complete hybrid and multi-cloud network observability.
Before co-founding Kentik, Biegel was responsible for sales in Northern California and the Pacific Northwest at Internap, a global provider of performance-driven, secure hybrid infrastructure solutions, where he led his regions to record-breaking performance. Biegel graduated with honors from DePaul University with a BA in Economics.
“Justin is a perfect addition to our advisory bench,” said Raphael Maunier, COO and co-Founder, OpsMill. “He’s worked across the infrastructure and networking spaces. Specifically, his career has taught him the increasing importance – and challenge – of network automation today.”
The move underscores OpsMill’s continuing efforts to enhance its Board of Directors with proven networking leaders.
About OpsMill
OpsMill is the infrastructure automation platform company, bringing the best practices and features of the industry’s leading automation approaches together in a single, scalable, and extensible platform so that infrastructure, cloud, network, and security teams can focus on innovation rather than integrating toolsets. Infrahub by OpsMill is the industry’s leading open-source integrated infrastructure automation platform. OpsMill is backed by Serena Capital, Partech, OVNI Capital, Kima Ventures and Better Angle. For more information, visit OpsMill.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813268658/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom